DepoBupivacaine Marketing Opportunity - Pacira Pharmaceuticals, Inc.

Pacira intends to commercialize DepoBupivacaine™ in the United States.

DepoBupivacaine is currently partnered with Maruho in Japan, where it is undergoing clinical studies for the management of postsurgical pain.

DepoBupivacaine:

Duration of action could significantly differentiate the product from available local anesthetics agents, providing 72 hours of pain relief
Unique formulation of a well known medication, bupivacaine, is expected to grow the market dramatically
Anticipated to offer superior efficacy and health economic benefits versus bupivacaine

Pacira is currently seeking partners for the European Union and the rest of the world.

If your company would like to learn more about this licensing opportunity, please contact us at busdev@pacira.com.